^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yidafan (ivonescimab)

    i
    Other names: AK112, AK 112, AK-112, SMT112, SMT-112, SMT 112
    Company:
    Akesobio, Summit Therapeutics
    Drug class:
    PD1 inhibitor, VEGF inhibitor
    Related drugs:
    23h
    ORIGIN2: Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Swiss Cancer Institute | Trial completion date: Mar 2029 --> Jul 2029 | Initiation date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2028 --> Jul 2028
    Trial completion date • Trial initiation date • Trial primary completion date • Checkpoint inhibition
    |
    CD4 (CD4 Molecule)
    |
    gemcitabine • Yidafan (ivonescimab)
    5d
    A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=66, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1/2 trial
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Datroway (datopotamab deruxtecan-dlnk) • Yidafan (ivonescimab)
    5d
    A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Yidafan (ivonescimab)
    7d
    Oncologic strategies and options for the management of metastatic thymic carcinoma. (PubMed, Mediastinum)
    Novel therapeutic approaches are emerging, including PRMT5 inhibitors in MTAP-deficient tumors, TROP-2-directed antibody-drug conjugates (e.g., sacituzumab govitecan), and chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin. Bispecific agents such as bintrafusp alfa and ivonescimab, which co-target various pathways, offer innovative strategies. Despite these advances, TC remains a challenging malignancy with no standardized treatment algorithm. Collaborative efforts across institutions will be essential to accelerate progress and improve outcomes in this rare disease.
    Review • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • MTAP (Methylthioadenosine Phosphorylase) • MSLN (Mesothelin)
    |
    KIT mutation
    |
    Trodelvy (sacituzumab govitecan-hziy) • bintrafusp alfa (M7824) • Yidafan (ivonescimab)
    13d
    AK112-305: Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=536, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Yidafan (ivonescimab)
    14d
    A Study of Ivonescimab in People With Leiomyosarcoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    Yidafan (ivonescimab)
    20d
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)
    20d
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    22d
    Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC (clinicaltrials.gov)
    P1, N=288, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • Tevimbra (tislelizumab-jsgr) • Ivesa (firmonertinib) • Yidafan (ivonescimab)
    29d
    SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    trastuzumab rezetecan (SHR-A1811) • Yidafan (ivonescimab)
    30d
    Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study (clinicaltrials.gov)
    P2, N=60, Enrolling by invitation, Sun Yat-sen University
    New P2 trial
    |
    Yidafan (ivonescimab)
    1m
    Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=87, Recruiting, Akeso | Trial completion date: Dec 2024 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Yidafan (ivonescimab) • drebuxelimab (AK119)